

7. Holly EA, Kelly JW, Shpall SN, Chiu SH. Number of melanocytic nevi as a major risk factor for malignant melanoma. *J Am Acad Dermatol* 1987;17:459-68.
8. Kopf AW, Friedman RJ, Rigel DS. Atypical mole syndrome. *J Am Acad Dermatol* 1990;22:117-8.
9. Marghoob AA, Kopf AW, Rigel DS, Bart RS, Friedman RJ, Yadav S, et al. Risk of cutaneous malignant melanoma in patients with "classic" atypical-mole syndrome: a case-control study. *Arch Dermatol* 1994;130:993-8.
10. Rigel DS, Friedman RJ, Kopf AW, Weltman R, Prioleau PG, Safai B, et al. Importance of complete cutaneous examination for the detection of malignant melanoma. *J Am Acad Dermatol* 1986;14:857-60.
11. Tiersten AD, Grin CM, Kopf AW, Gottlieb GJ, Bart RS, Rigel DS, et al. Prospective follow-up for malignant melanoma in patients with atypical-mole (dysplastic-nevus) syndrome. *J Dermatol Surg Oncol* 1991;17:44-8.
12. Slue W, Kopf AW, Rivers JK. Total-body photographs of dysplastic nevi. *Arch Dermatol* 1988;124:1239-43.
13. Steiner A, Pehamberger H, Wolff K. In vivo epiluminescence microscopy of pigmented skin lesions: II, diagnosis of small pigmented skin lesions and early detection of malignant melanoma. *J Am Acad Dermatol* 1987;17:584-91.
14. MacKie RM, Freudenberger T, Aitchison TC. Personal risk-factor chart for cutaneous melanoma. *Lancet* 1989;2:487-90.
15. Tucker MA, Fraser MC, Goldstein AM, Elder DE, Guerry Dt, Or-ganic SM. Risk of melanoma and other cancers in melanoma-prone families. *J Invest Dermatol* 1993;100(Suppl):350-55.
16. Holman CD, Armstrong BK. Cutaneous malignant melanoma and indicators of total accumulated exposure to the sun: an analysis separating histogenetic types. *J Natl Cancer Inst* 1984;73:75-82.
17. Marghoob AA, Slade J, Salopek TG, Kopf AW, Bart RS, Rigel DS. Basal cell and squamous cell carcinomas are important risk factors for cutaneous malignant melanoma: screening implications. *Cancer* 1995;75:707-14.
18. Lindelof B, Sigurgeirsson B, Wallberg P, Eklund G. Occurrence of other malignancies in 1973 patients with basal cell carcinoma. *J Am Acad Dermatol* 1991;25:245-8.
19. Green AC, O'Rourke MG. Cutaneous malignant melanoma in association with other skin cancers. *J Natl Cancer Inst* 1985;74:977-80.
20. Pehamberger H, Binder M, Steiner A, Wolff K. In vivo epiluminescence microscopy: improvement of early diagnosis of melanoma. *J Invest Dermatol* 1993;100(Suppl):356-62S.
21. Nachbar F, Stolz W, Merkle T, Cognetta AB, Vogt T, Landthaler M, et al. The ABCD rule of dermatoscopy: high prospective value in the diagnosis of doubtful melanocytic skin lesions. *J Am Acad Dermatol* 1994;30:551-9.
22. MacKie RM, McHenry P, Hole D. Accelerated detection with prospective surveillance for cutaneous malignant melanoma in high-risk groups. *Lancet* 1993;341:1618-20.

CORRECTION

Answers to CME examination for Brecher AR, Orlow SJ. Oral retinoid therapy for dermatologic conditions in children and adolescents (*J Am Acad Dermatol* 2003;49:186 [August])

The answer to question 1 from the CME examination ("Which of the following is Food and Drug Administration–approved for use in children younger than 12 years?") should be choice "e," not "b" as given.